Opioid Induced Constipation Drugs Market Size & Share 2024 – 2032

Opioid Induced Constipation Drugs Market Size

Opioid Induced Constipation Drugs Market was valued at around USD 2.1 billion in 2023 and is expected to grow at 4.8% CAGR during 2024 to 2032, driven by the increasing use of opioids coupled with the rising prevalence of gastrointestinal disorders.

The increasing use of opioids has become a pervasive healthcare concern, with a rising number of patients relying on these potent pain relievers for various medical conditions. However, alongside the benefits of opioid medications, there is a growing recognition of their adverse effects, particularly opioid-induced constipation (OIC), requiring the use of drugs for the treatment of these adverse conditions.
 

Moreover, as the incidence of gastrointestinal disorders due to opioid use increases, there is a corresponding expansion of the patient pool actively seeking relief from opioid-induced constipation. This growing demographic of individuals experiencing gastrointestinal complications necessitates effective pharmaceutical interventions to alleviate constipation symptoms. OIC drugs, designed to specifically target constipation linked to opioid use, become essential in meeting the therapeutic needs of this expanding patient population, driving the market's growth.
 

Opioid induced constipation drugs refer to pharmaceutical agents specifically formulated to manage and alleviate constipation caused by the use of opioid medications. These drugs are designed to address the unique challenges of constipation associated with opioid use disorder, providing relief by promoting bowel movements and easing symptoms without compromising the analgesic effects of opioids.
 

Opioid Induced Constipation Drugs Market Trends

As the understanding of opioid-induced constipation evolves and the demand for more efficacious and targeted interventions rises, increased investment in R&D becomes a pivotal force shaping the trajectory of opioid induced constipation drugs industry.
 

• Increased R&D funding enables the exploration of target-specific therapies designed to address the unique challenges of opioid induced constipation. The focus on precision medicine and therapies that selectively target the underlying mechanisms of constipation enhances the efficacy of treatments, marking a significant advancement in the field.
   
• Moreover, the surge in R&D expenditure contributes to the development of OIC drugs with improved safety profiles and tolerability. Pharmaceutical companies invest in refining formulations to minimize side effects, ensuring that new treatments are not only effective but also well-tolerated, enhancing patient compliance and satisfaction.
   
• Additionally, increased investment allows for a shift towards personalized medicine, with tailored interventions based on individual patient profiles. R&D efforts aim to identify biomarkers and patient characteristics that influence OIC, paving the way for customized treatments that address the specific needs of diverse patient populations. Such advancements are gaining the attention of healthcare professionals and patients resulting in increasing demand in the market.
   

Opioid Induced Constipation Drugs Market Analysis

The opioid induced constipation drugs industry by drug class is categorized into peripherally acting mu-opioid receptor agonists (PAMORAs), chloride channel-2 activators, laxatives, proton pump inhibitors, anti-diarrheal, and other drug classes. The peripherally acting mu-opioid receptor agonists (PAMORAs) segment was reached USD 706.3 million in 2023.
 

• PAMORAs represent a class of pharmaceuticals specifically designed to alleviate constipation associated with opioid use, addressing a critical need in patient care. PAMORAs distinguish themselves by selectively targeting peripheral mu-opioid receptors in the gastrointestinal tract, offering a mechanism of action tailored to the specific challenges of opioid-induced constipation. This distinct approach ensures the efficacy of PAMORAs in alleviating constipation while preserving the analgesic effects of opioids.  
   
• Moreover, the ability of PAMORAs to enhance bowel function goes beyond mere symptomatic relief, fostering improved patient satisfaction. By promoting regular bowel movements, patients experience a tangible improvement in their overall well-being. Due to such advantages, the segment is anticipated to grow over the forecast period.
   

The opioid induced constipation drugs market by prescription type is categorized into prescribed drugs and over-the-counter (OTC) drugs. The prescribed drugs segment exceeded USD 1.3 billion in 2023.
 

• The dominance of prescribed drugs in OIC treatment underscores the reliance on specialized pharmacotherapy to effectively manage constipation induced by opioid medications. Healthcare providers often opt for prescription-based solutions that specifically target the gastrointestinal complications associated with opioids, offering patients tailored and clinically proven options to alleviate OIC symptoms.  
   
• Notable prescribed drugs like naloxegol, lubiprostone, and naldemedine form the cornerstone of OIC treatment. These medications have demonstrated significant efficacy in addressing opioid-induced constipation and are widely recognized for their therapeutic benefits. The inclusion of such major prescribed drugs further solidifies the dominance of pharmaceutical interventions in OIC management, showcasing their effectiveness in alleviating constipation symptoms associated with opioid use, driving segmental growth.
   

Based on the route of administration, the opioid induced constipation drugs market is segmented into oral and injectable. The oral segment is anticipated to reach USD 2.4 billion by 2032.
 

• Oral medications provide a convenient and non-invasive way for individuals to manage constipation associated with opioid use. These oral drugs contribute to the growth of OIC treatment by enhancing patient compliance. The ease of oral administration aligns with patient preferences, fostering higher adherence to prescribed regimens. This improved compliance results in more effective constipation management, positively impacting patient outcomes and reinforcing the role of oral drugs in the overall treatment paradigm.
   
• Further, the availability of diverse oral therapeutic options for OIC further propels their role as a growth driver. Patients have access to a range of oral medications specifically designed to address opioid-induced constipation, allowing healthcare providers to tailor treatment plans based on individual patient needs. This diversity in oral drug offerings amplifies their significance in the comprehensive management of OIC, contributing to the market growth positively.
   

Learn more about the key segments shaping this market

Download Free PDF

The opioid induced constipation drugs market by distribution channel is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominates the market with a revenue around USD 1 billion in 2023.
 

• Hospital pharmacies serve as central points where patients receive medical care and obtain their prescribed medications. They have direct access to patients who may require treatment for opioid induced constipation. This increased access to patients makes the hospital pharmacies the prominent distributer of the opioid induced constipation.
   
• Moreover, hospitals pharmacies have facilities equipped to store opioid induced constipation under appropriate conditions to maintain their stability and integrity. They adhere to strict guidelines and regulations for the storage and handling of medications to ensure their safety and efficacy.
   

North America opioid induced constipation drugs market size surpassed USD 858.2 million in 2023 and is predicted to witness substantial market growth over 2024-2032.
 

• The advanced healthcare infrastructure in North America plays a pivotal role in fostering the growth of opioid induced constipation drugs. With well-established healthcare systems and a focus on comprehensive patient care, the region is at the forefront of addressing opioid-related complications. This includes the need for effective medications to manage constipation, contributing to the robust demand for OIC drugs and driving market expansion.
   
• Moreover, North America experiences a notable increase in the prevalence of gastrointestinal disorders, compounding the challenges associated with opioid-induced constipation. For instance, according to an article published by Medscape, in 2020, in North America alone, chronic constipation affected approximately 63 million people. The co-occurrence of opioid use and gastrointestinal disorders intensifies the demand for specialized OIC drugs, reflecting the interconnected nature of these healthcare concerns, further fueling demand.
   

Opioid Induced Constipation Drugs Market Share

The opioid induced constipation drugs industry is fragmented in nature, with various large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel treatments with improved efficiency and cost-effectiveness are among a key market strategy for opioid induced constipation drug manufacturers.
 

Opioid Induced Constipation Drugs Market Companies

Some of the eminent participants operating in the opioid induced constipation drugs industry include:

• Atlantis Consumer Healthcare Inc.
• Bausch Health Companies Inc.
• Bayer AG
• Cumberland Pharmaceuticals Inc.
• Mallinckrodt Pharmaceuticals
• Sanofi
• Shionogi & Co., Ltd.
• Valinor Pharma, LLC
   

Opioid Induced Constipation Drugs Industry News

• In December 2021, Shionogi & Co., Ltd. announced that Symproic has been approved in Taiwan for the treatment of opioid-induced constipation in adult patients. Symproic is a peripherally-acting mu-opioid receptor antagonist developed by Shionogi. This approval is expected to enhance customer base and expand to new geographies.
   

This opioid induced constipation drugs market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Class

• Peripherally acting mu-opioid receptor agonists (PAMORAs)
• Chloride channel-2 activators
• Laxatives
• Proton pump inhibitors
• Anti-diarrheal
• Other drug classes

Market, By Prescription Type

• Prescribed drugs
• Over-the-counter (OTC) drugs

Market, By Route of Administration 

• Oral
• Injectable

Market, By Distribution Channel 

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa